HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With PureZzzs, P&G Stretches ZzzQuil OTC Sleep Brand Into Supplement Space

This article was originally published in The Rose Sheet

Executive Summary

P&G will launch Vicks ZzzQuil PureZzzs in late February as a drug-free, melatonin-based sleep aid, CFO Jon Moeller says. P&G hopes to reach $4.5bn in e-commerce sales in 2018, up from $3bn in 2017.

You may also be interested in...



P&G Trims Media Spending, Gets 'Lean' From Production To Market

P&G reduces "media waste" by 20% in 2017 and sees further cost-reduction opportunities through private marketplace deals with media companies. During an investor conference, CEO David Taylor says P&G is responding to retailer pressure with a “lean innovation” approach to move products to market more quickly.

P&G Trims Media Spending, Gets 'Lean' From Production To Market

P&G reduces "media waste" by 20% in 2017 and sees further cost-reduction opportunities through private marketplace deals with media companies. During an investor conference, CEO David Taylor says P&G is responding to retailer pressure with a “lean innovation” approach to move products to market more quickly.

P&G Trims Media Spending, Gets 'Lean' From Production To Market

P&G reduces "media waste" by 20% in 2017 and sees further cost-reduction opportunities through private marketplace deals with media companies. During an investor conference, CEO David Taylor says P&G is responding to retailer pressure with a “lean innovation” approach to move products to market more quickly.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel